CE-VST01-JC / Cellevolve Bio - LARVOL DELTA

AAN to Mark 75th Anniversary at 2023 Annual Meeting (AJMC) - "Spencer’s abstract...highlighted in the AAN Annual Meeting Top Science Press Conference held last week. The other abstracts were...from Marianna Spatola, MD, PhD, Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, and...from George Ambalathingal, PhD, QIMR Berghofer Medical Research Institute, Queensland, Australia."

Clinical data • CNS Disorders • Epilepsy

Discussant: CE-VST01-JC: a Novel Allogeneic T-cell Based Immunotherapy for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) (AAN 2023) - No abstract available

CNS Disorders • Rare Diseases

Presenter: CE-VST01-JC: a Novel Allogeneic T-cell Based Immunotherapy for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) (AAN 2023) - No abstract available

CNS Disorders • Rare Diseases

ASCEND-JC: A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Cellevolve Bio Inc | Trial completion date: Jul 2024 ➔ Apr 2025

Trial completion date • CNS Disorders • Rare Diseases

ASCEND-JC: A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Cellevolve Bio Inc

New P2 trial • CNS Disorders • Rare Diseases